Immunology / Virology & Vaccines

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Chemical engineering #Clinical specialities #Drug development #Enabling technologies #Flow Cytometry #Genetics / genomes #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead optimisation #Microfluidics #PCR #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Toxicology

Creating vaccines drop by drop

By Richard Gray The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways, not least in the… Read More

#Covid-19 #Exclusive Content

#Biomarkers #Immunology / Virology & Vaccines #Translational #Translational chemistry

The Native Antigen Company Introduces Novel Coronavirus Antigens

Newly developed recombinant antigens derived specifically from 2019-nCoV for use in infectious disease research, and assay and vaccine development. The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced… Read More

#News

#Biomarkers #Chemistry #Immunology #Immunology / Virology & Vaccines #RNA

The Native Antigen Company Introduces Antigen and Antibody Conjugation Kits

Highly scalable kits enable researchers to prepare liquid-stable antigen and antibody conjugates with a wide range of labels including enzymes, fluorochromes, and biotin. The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic… Read More

#News

#Business #Gene therapy #Immunology / Virology & Vaccines #RNA

BIA Separations and University of Zagreb Sign License Agreement

BIA Separations and University of Zagreb Sign License Agreement to Commercialize Novel Elution Method for Virus and Viral Vector purification. Agreement gives BIA Separations access to proprietary technology to better preserve integrity, infectivity and potency of immunoaffinity-purified viral vectors for gene therapy Ajdovšcina, Slovenia… Read More

#News

#Clinical specialities #Immunology / Virology & Vaccines #Protein chemistry / Proteomics #Therapeutics

Miltenyi Biotec launches tool for coronavirus-specific T cell research

Miltenyi Biotec has launched its SARS-CoV-2 PepTivator Peptide Pools, a new addition to its PepTivator Portfolio specifically developed to help researchers currently investigating COVID-19 Based on decades worth of experience in developing products for virus-specific T cell research, SARS-CoV-2 PepTivator Peptide Pools work by stimulating T cells specific… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Genetics / genomes #High Content Screening #Immunology / Virology & Vaccines #RNA

The most discussed and shared scientific research of 2019

Climate crisis, artificial intelligence, and vaccines top the list of 2019’s most discussed research. From the increasing use of artificial intelligence to the climate emergency facing us all, many of this year’s most polarizing issues feature in the Altmetric Top 100, released today. The… Read More

#News

#Biologics / Biotechnology #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology #Immunology / Virology & Vaccines #Pathology #Preclinical #RNA

NIH-Moderna investigational COVID-19 vaccine shows promise in mouse studies

The vaccine is currently being evaluated in Phase 3 clinical testing. The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More

#Covid-19 #News

#Business #Drug development #Drug discovery #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Preclinical #Regulatory #Stem cells

Cancer Research UK collaborate to develop head and neck cancer vaccine

This a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC) HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the… Read More

#Cancer Research #News

#Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

Phase III clinical trial of investigational vaccine for COVID-19 begins in US

Multi-site trial to test candidate developed by Moderna and NIH. A Phase III clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun. The vaccine, known as mRNA-1273, was co-developed by the Cambridge, Massachusetts-based biotechnology company Moderna and… Read More

#Covid-19 #News

#Academic #Business #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK government advises drug companies to stockpile in case of Brexit disruption

Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer,… Read More

#Covid-19 #News

#Business #Clinical trials #Drug development #Drug discovery #Imaging #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA

GSK and Sanofi to supply US government with 100 million doses of COVID-19 vaccine

Sanofi and GSK have announced a collaborative effort with the US government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza… Read More

#Covid-19 #News

#Immunology / Virology & Vaccines #Regulatory

Sanofi and GSK in discussions with EC to supply COVID-19 vaccine

Sanofi and GSK are in advanced discussions with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine. The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an… Read More

#Covid-19 #News

#Business #Drug development #Drug discovery #Enabling technologies #Immunology #Immunology / Virology & Vaccines #Lead discovery #Regulatory #RNA #Stem cells

GSK and CureVac in mRNA technology collaboration

27 July 2020 Image: CDC GlaxoSmithKline and CureVac are collaborating for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. mRNA (messenger RNA) technology is… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical specialities #Clinical trials #Drug discovery #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Protein chemistry / Proteomics #Therapeutics

PerkinElmer launches virtual open access Covid-19 Data Dashboards to accelerate research

The company has launched two online, free-to-access Covid-19 Data Dashboards to aid the global scientific community accelerate the discovery of antivirals and vaccines. The informatics tools are set to help scientists access, aggregate and analyse drug compound and clinical trial data and are powered by PerkinElmer’s data analytics… Read More

#Covid-19 #News

#Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Precision medicine #RNA #Therapeutics

Over £100m UK cash boost to produce millions of doses of COVID-19 vaccine

The UK’s capability to manufacture vaccines has received a substantial boost, as the UK government has announced an additional £100 million to ensure that any successful COVID-19 vaccine can be produced at scale in the UK. The investment will fund a Cell and Gene Therapy Catapult Manufacturing Innovation… Read More

#Covid-19 #News

#Academic #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Immunology / Virology & Vaccines #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Top Ten UK organisations for animal research announced

Understanding Animal Research (UAR), which promotes openness about animal research, has released a list of the ten organisations in Great Britain that carry out the highest number of animal procedures in medical, veterinary and scientific research. These statistics are freely available on the organisations’ websites as part of… Read More

#Covid-19 #News